Earnings Call · Q2 FY2026·2026-08-13

Q2 26EPS -3.33%·Rev n/aQ1 26EPS +25.97%·Rev n/aQ4 25EPS +17.65%·Rev n/aQ3 25EPS +23.53%·Rev n/a⚠ consensus missing

MiNK Therapeutics, Inc. INKT

Stephanie Perdenacar — Investor Relations, NK Therapeutics

Dr. Jennifer Buell — President and Chief Executive Officer

Melissa Orilall — Principal Financial Officer

Automated Q&A System — Teleconference System Prompt

−3.2%1d on move date3d−1.2%5d−2.0%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more INKT calls or request research access.

More INKT calls Browse calls Request research access